| dc.description.abstract | The plant species in the family Aristolochiaceae consists of various important bioactive
compounds, and they are used as functional ingredients in the development of therapeutic agents
to act against diseases including diabetes. The main objective of this review is to identify the
glucose-lowering potencies regarding the diabetic mellitus of plant species in the family
Aristolochiaceae. This was conducted by analyzing the alpha-glucosidase inhibition in the alphaglucosidase
inhibitory assay, the alpha-amylase dehydrogenase rate in the alpha-amylase
inhibitory assay, and glucose reduction in the diabetic rat model. In the diabetic rat model, root
ethanolic extract of Aristolochia ringens showed the highest glucose reduction with the
Streptozotocin (STZ) diabetogenic agent, which is 113.1±1.8 mg/dl. The leaf ethanol extract of
Aristolochia indica showed the highest glucose reduction with the alloxan diabetogenic agent,
which is 5.28±0.37 mg/dl. When using dexamethasone as a diabetogenic agent, methanolic
extract of the whole plant of Aristolochia bracteolata showed the highest glucose reduction, which
is 124.5±1.231 mg/dl. In α- glucosidase inhibitory assay, ethyl acetate root extract of Aristolochia
longa showed the highest IC50 value which is 0.199±0.014 mg/ml. In the α- amylase inhibitory
assay, whole plant methanolic extract of Aristolochia indica showed the highest α-amylase
dehydrogenase rate which is 60.12 ±0.46 nm/min/mg protein. The genus Aristolochia in the
family Aristolochiaceae showed significant glucose-lowering potency. Moreover, the importance
of using species in the family Aristolochiaceae in the management of diabetes should be identified
and accepted for suitable alternative medicines in future studies. | en_US |
